The key qualifying phrase to Gilead Sciences’ solid second quarter earnings was “excluding Veklury.” That’s because the Covid-19 treatment was the spoiler dropoff in a consistent set of increases across therapy areas inside Gilead’s $6.6 billion in Q2 revenue.
The decrease wasn’t a surprise to analysts, although Veklury did come…
Click here to view original post
